newsfilter
← Latest News
GlobeNewswire·

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

  • Anavex Life Sciences Corp. (NASDAQ: AVXL) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026.
  • The presentation will take place at the Westin St. Francis in San Francisco, CA, from 4:30 PM to 5:10 PM Pacific Time.
  • Christopher U. Missling, PhD, President & Chief Executive Officer, will lead the company's presentation session.
  • An audio webcast of the session will be available on the company's website, with a replay accessible later on the same day.
  • The 44th Annual Healthcare Conference is scheduled for January 12-15, 2026, in San Francisco, CA.
  • The company's lead candidate, ANAVEX®2-73 (blarcamesine), completed Phase 2a, Phase 2b/3, Phase 2 proof-of-concept, Phase 2, Phase 3, & Phase 2/3 clinical trials for Alzheimer's disease, Parkinson's disease dementia, & Rett syndrome.
  • ANAVEX®2-73 targets SIGMAR1 & muscarinic receptors to restore cellular homeostasis & has shown potential to treat CNS disorders including epilepsy.
  • ANAVEX®3-71 is a clinical-stage candidate targeting SIGMAR1 & M1 muscarinic receptors that demonstrated disease-modifying activity against Alzheimer's disease hallmarks in preclinical mouse models.
  • Anavex is a publicly traded biopharmaceutical company developing novel therapeutics for neurodegenerative, neurodevelopmental, neuropsychiatric, pain, & cancer disorders.